MedTrace Logo

Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET

NCT05889312 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2025-04-04

No results posted yet for this study

Summary

Prospective single centre non-randomised exploratory observational study to measure changes in tumour cellular redox status with 18F-FSPG PET in stage 3 non-small cell lung cancer (NSCLC) and stage 3 and 4 head and neck squamous cell cancer (HNSCC) at baseline and during standard of care treatment, and to compare this with 18F-FDG PET/CT and RECIST 1.1 response at 12 weeks.

Conditions

  • Cancer
  • Diagnosis
  • Resistant Cancer
  • Response, Acute Phase

Interventions

DIAGNOSTIC_TEST

18F-FSPG PET/CT in NSCLC

Stage 3 NSCLC with radical curative intent at baseline (pre-treatment) and at 4-8 weeks into treatment.

DIAGNOSTIC_TEST

18F-FSPG PET/CT in HNSCC

Stage 3 and 4 HNSCC with radical curative intent at baseline and at 2-4 weeks into treatment.

Sponsors & Collaborators

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-19
Primary Completion
2026-09-30
Completion
2027-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05889312 on ClinicalTrials.gov